Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 210,000 | 7,000 | -129,000 | -85,000 | 213,000 |
| Depreciation Amortization | 20,000 | 28,000 | 15,000 | 21,000 | 22,000 |
| Income taxes - deferred | -46,000 | 7,000 | -65,000 | N/A | N/A |
| Accounts receivable | 3,000 | -1,000 | -33,000 | -21,000 | -25,000 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | -98,000 | 201,000 |
| Other Working Capital | -257,000 | -46,000 | -294,000 | 125,000 | 173,000 |
| Other Operating Activity | 43,000 | 41,000 | 206,000 | 54,000 | -231,000 |
| Operating Cash Flow | $-27,000 | $36,000 | $-300,000 | $-4,000 | $353,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -20,000 | -17,000 | -45,000 | -245,000 | N/A |
| PPE Investments | -66,000 | -29,000 | -8,000 | -5,000 | -4,000 |
| Net Acquisitions | N/A | N/A | -129,000 | N/A | N/A |
| Sale Of Investment | 20,000 | 117,000 | 129,000 | 27,000 | N/A |
| Purchase Sale Intangibles | -1,000 | -2,000 | -45,000 | 0 | -10,000 |
| Other Investing Activity | 0 | -2,000 | -42,000 | 0 | -10,000 |
| Investing Cash Flow | $-66,000 | $69,000 | $-95,000 | $-223,000 | $-14,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 332,000 | N/A | N/A | 250,000 |
| Debt Repayment | -17,000 | -240,000 | -12,000 | -3,000 | -236,000 |
| Common Stock Issued | 2,000 | 3,000 | 3,000 | 2,000 | 1,000 |
| Common Stock Repurchased | -11,000 | -173,000 | -33,000 | -90,000 | -101,000 |
| Other Financing Activity | -4,000 | -24,000 | -22,000 | -9,000 | -8,000 |
| Financing Cash Flow | $-30,000 | $-102,000 | $-64,000 | $-100,000 | $-94,000 |
| Exchange Rate Effect | -1,000 | N/A | 1,000 | -1,000 | -1,000 |
| Beginning Cash Position | 319,000 | 316,000 | 774,000 | 1,102,000 | 858,000 |
| End Cash Position | 195,000 | 319,000 | 316,000 | 774,000 | 1,102,000 |
| Net Cash Flow | $-124,000 | $3,000 | $-458,000 | $-328,000 | $244,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | -27,000 | 36,000 | -300,000 | -4,000 | 353,000 |
| Capital Expenditure | -66,000 | -29,000 | -8,000 | -5,000 | -4,000 |
| Free Cash Flow | -93,000 | 7,000 | -308,000 | -9,000 | 349,000 |